Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 15 of 15 for “"Plerixafor"”.

  1. Die retrospektive Analyse autologer Stammzellapheresate aus peripherem Blut nach Mobilisation mittels Granulozyten-Kolonie-stimulierendem Faktor und Hinzugabe von Plerixafor

    … der CXC-Motiv-Chemokinrezeptor 4 -Antagonist Plerixafor zugelassen. Ziel dieser Arbeit ist die retrospektive Analyse von Patienten, die am Universitätsklinikum Leipzig Plerixafor erhalten haben und bei denen eine HDT mit autologer HSZT geplant war. Es sollen insbesondere die Effektivität der …

    qucosa-diss

  2. Κινητοποίηση των αρχέγονων αιμοποιητικών κυττάρων και κινητική εμφύτευσης: προεκτάσεις για τη γονιδιακή θεραπεία της θαλασσαιμίας

    … We investigated the mobilization with G-CSF, Plerixafor or Plerixafor+G-CSF, in thalassemic, Hbbth3/45.2+ mice in terms of safety and efficacy, as well as the engraftment kinetics of the mobilized cells after competitive primary and noncompetitive secondary transplantation and transducibility …

    greece Repository record for Κινητοποίηση των αρχέγονων αιμοποιητικών κυττάρων και κινητική εμφύτευσης: προεκτάσεις για τη γονιδιακή θεραπεία της θαλασσαιμίας (opens in a new tab)

  3. Κυτταρική θεραπεία οξείας και χρόνιας ηπατικής βλάβης με χορήγηση κυττάρων μυελού των οστών ή με κινητοποιητές αιμοποιητικών στελεχιαίων κυττάρων

    … G-CSF, the most widely used mobilizing agent, Plerixafor, a novel mobilizing agent of HSCs, as well as their combination. Either single-agent mobilization or the combination of agents significantly ameliorated hepatic damage by decreasing fibrosis and restoring the abnormal vascular network in …

    greece Repository record for Κυτταρική θεραπεία οξείας και χρόνιας ηπατικής βλάβης με χορήγηση κυττάρων μυελού των οστών ή με κινητοποιητές αιμοποιητικών στελεχιαίων κυττάρων (opens in a new tab)

  4. DEVELOPING MULTI-OMICS ANALYSIS PIPELINE TO IDENTIFY NOVEL DRUG REPURPOSING TARGETS FOR COPD

    … targets. Literature search reported CRCX4 – Plerixafor as one prioritized targets-gene pair for drug repurposing. The bone marrow stimulant Plerixafor is currently being evaluated for COPD treatment in clinical trials, suggesting that our pipeline is finding promising drug repurposing …

    temple Repository record for DEVELOPING MULTI-OMICS ANALYSIS PIPELINE TO IDENTIFY NOVEL DRUG REPURPOSING TARGETS FOR COPD (opens in a new tab)

  5. Role of miR-9 and its target CXCR4 in head and neck cancers

    … and invasion. Whereas CXCR4 inhibition with plerixafor abrogated the oncogenic phenotype of CXCR4 overexpression and miR-9 knockdown. <br/>Our data indicates that miR-9 functions as a tumour suppressive mircoRNA in HPV negative HNSCCs via CXCR4 repression in cell lines and in HPV positive …

    kings Repository record for Role of miR-9 and its target CXCR4 in head and neck cancers (opens in a new tab) Download PDF for Role of miR-9 and its target CXCR4 in head and neck cancers (opens in a new tab)

  6. In vivo και ex vivo γονιδιακή θεραπεία της θαλασσαιμίας με χρήση ενός αδενο-ιικού φορέα γ-σφαιρίνης

    … of G-CSF (250μg/kg for 6 days) and Plerixafor (50μg/kg for 4 days). Forty minutes after the last dose of plerixafor the mice were intravenously injected with the HDAd-CRISPR-Dual vector allowing selective transduction of the human HSCs, as CD46 is not expressed on mouse HSCs. No …

    greece Repository record for In vivo και ex vivo γονιδιακή θεραπεία της θαλασσαιμίας με χρήση ενός αδενο-ιικού φορέα γ-σφαιρίνης (opens in a new tab)

  7. Angiotensin-(1-7): A Target for Stem Cell Mobilopathy and Vascular Repair in Diabetes

    … Ang-(1-7), in combination with G-CSF or plerixafor reversed the stem cell mobilopathy in diabetes. These beneficial effects of Ang-(1-7) were blunted in Mas receptor knockout (MasR-KO) mice. These results suggest that MasR is a promising target for the treatment of diabetic bone marrow …

    ndsu Repository record for Angiotensin-(1-7): A Target for Stem Cell Mobilopathy and Vascular Repair in Diabetes (opens in a new tab)

  8. Characterization of Normal and Preleukemic Hematopoietic Stem Cell Responses to Physiologic and Extra-Physiologic Oxygen Tension

    … blood mobilized with G-CSF alone or G-CSF and Plerixafor under physioxia resulted in a greater number of phenotypically defined long-term engrafting HSCs. Using high-resolution single cell sequencing to explore the molecular programs governing HSCs under physioxia, I identified increased …

    iupui Repository record for Characterization of Normal and Preleukemic Hematopoietic Stem Cell Responses to Physiologic and Extra-Physiologic Oxygen Tension (opens in a new tab)

  9. Using CXCR4 Antagonism and G-CSF to Induce Sustained Neutrophilia in Mice for Applications in Spinal Cord Injury Research

    … 4 (CXCR4) antagonism and we injected AMD3100 (Plerixafor), which is a drug known to target CXCR4. The second strategy we employed was to deliver G-CSF via a plasmid vector, injected directly into the bloodstream, to induce the proliferation of pre-neutrophil progenitor cells. To assess …

    tamu Repository record for Using CXCR4 Antagonism and G-CSF to Induce Sustained Neutrophilia in Mice for Applications in Spinal Cord Injury Research (opens in a new tab)

  10. Using CXCR4 Antagonism and G-CSF to Induce Sustained Neutrophilia in Mice for Applications in Spinal Cord Injury Research

    … 4 (CXCR4) antagonism and we injected AMD3100 (Plerixafor), which is a drug known to target CXCR4. The second strategy we employed was to deliver G-CSF via a plasmid vector, injected directly into the bloodstream, to induce the proliferation of pre-neutrophil progenitor cells. To assess …

    tamu Repository record for Using CXCR4 Antagonism and G-CSF to Induce Sustained Neutrophilia in Mice for Applications in Spinal Cord Injury Research (opens in a new tab)

  11. Regulation of human hematopoietic cells with short-term in vivo repopulating activity

    … colony stimulating factor (G-CSF) plus plerixafor (P) to administration of P alone. Blood and marrow samples were obtained from 10 normal adult donors before, during, and after treatment and then evaluated for their content of CD34⁺ cells, colony-forming cells (CFCs), long-term …

    ubc Repository record for Regulation of human hematopoietic cells with short-term in vivo repopulating activity (opens in a new tab) Download PDF for Regulation of human hematopoietic cells with short-term in vivo repopulating activity (opens in a new tab)

  12. Der Einfluss von Chemotherapien und G-CSF auf das Riechen und Schmecken beim Menschen

    … über 5–6 Tage (Lenograstim bzw. Filgrastim ± Plerixafor) verabreicht. Die Testmethoden umfassten einen Anamnesebogen zur Erfassung der subjektiven Wahrnehmung, Sniffing Sticks zur Testung der Riechfunktion und Schmecksprays zur Testung der Schmeckwahrnehmung. Die olfaktorische Riechschwelle …

    qucosa-diss

  13. Effects of Pharmacological and Genetic Disruption of Chemokine Receptor Cxcr4 In B-Cell Acute Lymphoblastic Leukemia

    The CXCR4 chemokine receptor plays a pivotal role in homing and retention of B-cell Acute Lymphoblastic Leukemia cells to bone marrow niches. The bone marrow stromal cells (BMSCs) constitutively secrete the CXCR4 ligand CXCL12, thus attracting leukemia cells and protecting them from cytotoxic …

    uthsc Repository record for Effects of Pharmacological and Genetic Disruption of Chemokine Receptor Cxcr4 In B-Cell Acute Lymphoblastic Leukemia (opens in a new tab)

  14. Η απόδοση της συλλογής αρχέγονων αιμοποιητικών κυττάρων περιφερικού αίματος με τον κυτταροδιαχωριστή Spectra Optia και οι παράγοντες που την επηρεάζουν

    … περιφερικό αίμα (σχήμα κινητοποίησης, χορήγηση Plerixafor και χρόνος χορήγησης, ημέρα συλλογής), στα χαρακτηριστικά του περιφερικού αίματος προ συλλογής (χρονικό διάστημα μεταξύ λήψης αίματος από το περιφερικό προ συλλογής και έναρξης συλλογής, συγκέντρωση λευκών αιμοσφαιρίων και αιμοπεταλίων, …

    athens Repository record for Η απόδοση της συλλογής αρχέγονων αιμοποιητικών κυττάρων περιφερικού αίματος με τον κυτταροδιαχωριστή Spectra Optia και οι παράγοντες που την επηρεάζουν (opens in a new tab)